SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-18-009223
Filing Date
2018-05-09
Accepted
2018-05-09 16:50:47
Documents
76
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20180331_10q.htm 10-Q 887856
2 EXHIBIT 10.1 ex_112907.htm EX-10.1 32749
3 EXHIBIT 31.1 ex_112908.htm EX-31.1 9469
4 EXHIBIT 31.2 ex_112909.htm EX-31.2 9482
5 EXHIBIT 32.1 ex_112910.htm EX-32.1 4678
6 EXHIBIT 32.2 ex_112911.htm EX-32.2 4724
  Complete submission text file 0001437749-18-009223.txt   6268810

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT navb-20180331.xml EX-101.INS 1172744
8 XBRL TAXONOMY EXTENSION SCHEMA navb-20180331.xsd EX-101.SCH 61477
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20180331_cal.xml EX-101.CAL 45853
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20180331_def.xml EX-101.DEF 617753
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20180331_lab.xml EX-101.LAB 394851
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20180331_pre.xml EX-101.PRE 622811
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 18819095
SIC: 2835 In Vitro & In Vivo Diagnostic Substances